RxDoctor Payments Data

Naciye Kalafat, MD

Psychiatry · Green Bay, WINPI 1861459612

Payments from drug & device makers

$2,339in general payments, 2019–2025

Across 135 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$302
  • Otsuka America Pharmaceutical, Inc.$279
  • Teva Pharmaceuticals USA, Inc.$275
  • Neurocrine Biosciences, Inc.$172
  • Lundbeck LLC$163
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$146
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,15392%
  • Education$1868%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,339 in reported general payments places this provider in the 85th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$9,491
Medicare patients
25
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl33$51,386
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl105$19,188
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$6,413
BelsomraSuvorexant12$5,897
Lisdexamfetamine Dimesylate16$2,655
Duloxetine Hcl40$1,526
Gabapentin51$1,229
Ziprasidone Hcl13$1,208
Quetiapine Fumarate37$1,103
Olanzapine26$892
Trazodone Hcl23$872
Buspirone Hcl43$818
Aripiprazole23$735
Clonazepam41$632
Venlafaxine Hcl ErVenlafaxine Hcl22$577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$302$51,38633 claims
Indivior Inc.Suboxone$41$6,41313 claims
MerckBelsomra$19$5,89712 claims
Almatica Pharma LLCSertraline Hcl$69$29913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →